Candel Therapeutics, Inc. announced that Francesca Barone has been named as the company's Chief Scientific Officer. Dr. Barone brings more than 20 years of experience in immunology, experimental medicine, and innovative drug development to help bring important new therapeutics to the clinic. Dr. Barone was previously the company's Vice President, Head of Research having joined the company in November 2020.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.49 USD | -4.61% | -0.09% | +481.14% |
05-30 | FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma | MT |
05-30 | Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+481.14% | 265M | |
+47.33% | 54.63B | |
-6.72% | 39.92B | |
+37.07% | 38.82B | |
+13.90% | 26.86B | |
-11.17% | 26.22B | |
-21.88% | 18.78B | |
+25.96% | 12.21B | |
+0.75% | 12.16B | |
+26.72% | 11.94B |
- Stock Market
- Equities
- CADL Stock
- News Candel Therapeutics, Inc.
- Candel Therapeutics, Inc. Appoints Dr. Francesca Barone as Chief Scientific Officer